# Gilead Sciences revenue entity: /record/gilead-sciences.md predicate: revenue page: /record/gilead-sciences/revenue as_of: 2026-11-08 cite: AsOf. "Gilead Sciences quarterly revenue: 8,300,000,000 United States dollar", as of 2026-09-30. Claim clm_64E20B8C7E0A, https://asof.is/claim/clm_64E20B8C7E0A, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm. As of November 8, 2026, the latest revenue figure on the AsOf record for Gilead Sciences is $8.3 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). Gilead Sciences's latest full-year revenue is $29.44 billion, dated December 31, 2025, from a primary source (sec.gov); the two periods are kept apart, never compared. 19 claims on Gilead Sciences's revenue, 1 open and 18 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted. ## Latest revenue The newest figure for a shorter period, the quarter ended September 30, 2026: a quarterly_revenue claim, kept apart from the full-year series. Every quarterly revenue figure: /record/gilead-sciences/quarterly_revenue.md - [Gilead Sciences](/record/gilead-sciences.md) | quarterly_revenue | 8,300,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_64E20B8C7E0A](/claim/clm_64E20B8C7E0A.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209526000039/0000882095-26-000039-index.htm ## Latest full-year revenue What the record asserts on 2026-11-08. - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 29,443,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_5E2D1C5DC1DC](/claim/clm_5E2D1C5DC1DC.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm ## Every dated value One claim per line, oldest first. Superseded claims stay visible. - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 4,230,045,000 United States dollar | valid 2007-12-31 to 2008-12-31 | conf 0.95 | superseded | superseded_by [clm_78AFDF7AC308](/claim/clm_78AFDF7AC308.md) | [clm_2896D3FD1A51](/claim/clm_2896D3FD1A51.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 5,335,750,000 United States dollar | valid 2008-12-31 to 2009-12-31 | conf 0.95 | superseded | superseded_by [clm_23ACEDC261B0](/claim/clm_23ACEDC261B0.md) | [clm_78AFDF7AC308](/claim/clm_78AFDF7AC308.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 7,011,383,000 United States dollar | valid 2009-12-31 to 2010-12-31 | conf 0.95 | superseded | superseded_by [clm_819CF52FBEB1](/claim/clm_819CF52FBEB1.md) | [clm_23ACEDC261B0](/claim/clm_23ACEDC261B0.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000119312510044753/0001193125-10-044753-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 7,949,420,000 United States dollar | valid 2010-12-31 to 2011-12-31 | conf 0.95 | superseded | superseded_by [clm_3C7AA6C6D6B9](/claim/clm_3C7AA6C6D6B9.md) | [clm_819CF52FBEB1](/claim/clm_819CF52FBEB1.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000119312511050041/0001193125-11-050041-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 8,385,385,000 United States dollar | valid 2011-12-31 to 2012-12-31 | conf 0.95 | superseded | superseded_by [clm_6D4418F572A9](/claim/clm_6D4418F572A9.md) | [clm_3C7AA6C6D6B9](/claim/clm_3C7AA6C6D6B9.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000119312512075335/0001193125-12-075335-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 9,702,517,000 United States dollar | valid 2012-12-31 to 2013-12-31 | conf 0.95 | superseded | superseded_by [clm_C43DA4F79044](/claim/clm_C43DA4F79044.md) | [clm_6D4418F572A9](/claim/clm_6D4418F572A9.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209513000015/0000882095-13-000015-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 11,201,688,000 United States dollar | valid 2013-12-31 to 2014-12-31 | conf 0.95 | superseded | superseded_by [clm_617CC39EB4D4](/claim/clm_617CC39EB4D4.md) | [clm_C43DA4F79044](/claim/clm_C43DA4F79044.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209514000013/0000882095-14-000013-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 24,890,000,000 United States dollar | valid 2014-12-31 to 2015-12-31 | conf 0.95 | superseded | superseded_by [clm_963EB0743197](/claim/clm_963EB0743197.md) | [clm_617CC39EB4D4](/claim/clm_617CC39EB4D4.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209515000008/0000882095-15-000008-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 32,639,000,000 United States dollar | valid 2015-12-31 to 2016-12-31 | conf 0.95 | superseded | superseded_by [clm_FC87519132B6](/claim/clm_FC87519132B6.md) | [clm_963EB0743197](/claim/clm_963EB0743197.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209516000039/0000882095-16-000039-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 30,390,000,000 United States dollar | valid 2016-12-31 to 2017-12-31 | conf 0.95 | superseded | superseded_by [clm_27E7D83B62B4](/claim/clm_27E7D83B62B4.md) | [clm_FC87519132B6](/claim/clm_FC87519132B6.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 26,107,000,000 United States dollar | valid 2017-12-31 to 2018-12-31 | conf 0.95 | superseded | superseded_by [clm_2C70360428CB](/claim/clm_2C70360428CB.md) | [clm_27E7D83B62B4](/claim/clm_27E7D83B62B4.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 22,127,000,000 United States dollar | valid 2018-12-31 to 2019-12-31 | conf 0.95 | superseded | superseded_by [clm_43120E77E428](/claim/clm_43120E77E428.md) | [clm_2C70360428CB](/claim/clm_2C70360428CB.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209519000006/0000882095-19-000006-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 22,449,000,000 United States dollar | valid 2019-12-31 to 2020-12-31 | conf 0.95 | superseded | superseded_by [clm_BCA2F683C1DE](/claim/clm_BCA2F683C1DE.md) | [clm_43120E77E428](/claim/clm_43120E77E428.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209520000006/0000882095-20-000006-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 24,689,000,000 United States dollar | valid 2020-12-31 to 2021-12-31 | conf 0.95 | superseded | superseded_by [clm_D6C1A036D30A](/claim/clm_D6C1A036D30A.md) | [clm_BCA2F683C1DE](/claim/clm_BCA2F683C1DE.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209521000008/0000882095-21-000008-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 27,305,000,000 United States dollar | valid 2021-12-31 to 2022-12-31 | conf 0.95 | superseded | superseded_by [clm_63D857B5C382](/claim/clm_63D857B5C382.md) | [clm_D6C1A036D30A](/claim/clm_D6C1A036D30A.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209522000007/0000882095-22-000007-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 27,281,000,000 United States dollar | valid 2022-12-31 to 2023-12-31 | conf 0.95 | superseded | superseded_by [clm_ABFE2CB3CF48](/claim/clm_ABFE2CB3CF48.md) | [clm_63D857B5C382](/claim/clm_63D857B5C382.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209523000007/0000882095-23-000007-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 27,116,000,000 United States dollar | valid 2023-12-31 to 2024-12-31 | conf 0.95 | superseded | superseded_by [clm_766F0DC2656D](/claim/clm_766F0DC2656D.md) | [clm_ABFE2CB3CF48](/claim/clm_ABFE2CB3CF48.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209524000007/0000882095-24-000007-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 28,754,000,000 United States dollar | valid 2024-12-31 to 2025-12-31 | conf 0.95 | superseded | superseded_by [clm_5E2D1C5DC1DC](/claim/clm_5E2D1C5DC1DC.md) | [clm_766F0DC2656D](/claim/clm_766F0DC2656D.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209525000006/0000882095-25-000006-index.htm - [Gilead Sciences](/record/gilead-sciences.md) | revenue | 29,443,000,000 United States dollar | valid 2025-12-31 to present | conf 0.95 | valid | [clm_5E2D1C5DC1DC](/claim/clm_5E2D1C5DC1DC.md) sources: https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm ## What replaced what - $4.23 billion (2007-12-31 to 2008-12-31, [clm_2896D3FD1A51](/claim/clm_2896D3FD1A51.md)) was replaced by $5.34 billion from 2008-12-31 ([clm_78AFDF7AC308](/claim/clm_78AFDF7AC308.md)) - $5.34 billion (2008-12-31 to 2009-12-31, [clm_78AFDF7AC308](/claim/clm_78AFDF7AC308.md)) was replaced by $7.01 billion from 2009-12-31 ([clm_23ACEDC261B0](/claim/clm_23ACEDC261B0.md)) - $7.01 billion (2009-12-31 to 2010-12-31, [clm_23ACEDC261B0](/claim/clm_23ACEDC261B0.md)) was replaced by $7.95 billion from 2010-12-31 ([clm_819CF52FBEB1](/claim/clm_819CF52FBEB1.md)) - $7.95 billion (2010-12-31 to 2011-12-31, [clm_819CF52FBEB1](/claim/clm_819CF52FBEB1.md)) was replaced by $8.39 billion from 2011-12-31 ([clm_3C7AA6C6D6B9](/claim/clm_3C7AA6C6D6B9.md)) - $8.39 billion (2011-12-31 to 2012-12-31, [clm_3C7AA6C6D6B9](/claim/clm_3C7AA6C6D6B9.md)) was replaced by $9.7 billion from 2012-12-31 ([clm_6D4418F572A9](/claim/clm_6D4418F572A9.md)) - $9.7 billion (2012-12-31 to 2013-12-31, [clm_6D4418F572A9](/claim/clm_6D4418F572A9.md)) was replaced by $11.2 billion from 2013-12-31 ([clm_C43DA4F79044](/claim/clm_C43DA4F79044.md)) - $11.2 billion (2013-12-31 to 2014-12-31, [clm_C43DA4F79044](/claim/clm_C43DA4F79044.md)) was replaced by $24.89 billion from 2014-12-31 ([clm_617CC39EB4D4](/claim/clm_617CC39EB4D4.md)) - $24.89 billion (2014-12-31 to 2015-12-31, [clm_617CC39EB4D4](/claim/clm_617CC39EB4D4.md)) was replaced by $32.64 billion from 2015-12-31 ([clm_963EB0743197](/claim/clm_963EB0743197.md)) - $32.64 billion (2015-12-31 to 2016-12-31, [clm_963EB0743197](/claim/clm_963EB0743197.md)) was replaced by $30.39 billion from 2016-12-31 ([clm_FC87519132B6](/claim/clm_FC87519132B6.md)) - $30.39 billion (2016-12-31 to 2017-12-31, [clm_FC87519132B6](/claim/clm_FC87519132B6.md)) was replaced by $26.11 billion from 2017-12-31 ([clm_27E7D83B62B4](/claim/clm_27E7D83B62B4.md)) - $26.11 billion (2017-12-31 to 2018-12-31, [clm_27E7D83B62B4](/claim/clm_27E7D83B62B4.md)) was replaced by $22.13 billion from 2018-12-31 ([clm_2C70360428CB](/claim/clm_2C70360428CB.md)) - $22.13 billion (2018-12-31 to 2019-12-31, [clm_2C70360428CB](/claim/clm_2C70360428CB.md)) was replaced by $22.45 billion from 2019-12-31 ([clm_43120E77E428](/claim/clm_43120E77E428.md)) - $22.45 billion (2019-12-31 to 2020-12-31, [clm_43120E77E428](/claim/clm_43120E77E428.md)) was replaced by $24.69 billion from 2020-12-31 ([clm_BCA2F683C1DE](/claim/clm_BCA2F683C1DE.md)) - $24.69 billion (2020-12-31 to 2021-12-31, [clm_BCA2F683C1DE](/claim/clm_BCA2F683C1DE.md)) was replaced by $27.31 billion from 2021-12-31 ([clm_D6C1A036D30A](/claim/clm_D6C1A036D30A.md)) - $27.31 billion (2021-12-31 to 2022-12-31, [clm_D6C1A036D30A](/claim/clm_D6C1A036D30A.md)) was replaced by $27.28 billion from 2022-12-31 ([clm_63D857B5C382](/claim/clm_63D857B5C382.md)) - $27.28 billion (2022-12-31 to 2023-12-31, [clm_63D857B5C382](/claim/clm_63D857B5C382.md)) was replaced by $27.12 billion from 2023-12-31 ([clm_ABFE2CB3CF48](/claim/clm_ABFE2CB3CF48.md)) - $27.12 billion (2023-12-31 to 2024-12-31, [clm_ABFE2CB3CF48](/claim/clm_ABFE2CB3CF48.md)) was replaced by $28.75 billion from 2024-12-31 ([clm_766F0DC2656D](/claim/clm_766F0DC2656D.md)) - $28.75 billion (2024-12-31 to 2025-12-31, [clm_766F0DC2656D](/claim/clm_766F0DC2656D.md)) was replaced by $29.44 billion from 2025-12-31 ([clm_5E2D1C5DC1DC](/claim/clm_5E2D1C5DC1DC.md)) ## Questions this record answers ### What is Gilead Sciences's current revenue? The latest figure on the record is $8.3 billion for the quarter ended September 30, 2026, from a primary source (sec.gov). The latest full-year figure is $29.44 billion, dated December 31, 2025, from a primary source (sec.gov). The record asserts both as of November 8, 2026. ### What was Gilead Sciences's revenue for the quarter ended September 30, 2026? $8.3 billion for the quarter ended September 30, 2026, dated September 30, 2026, from a primary source (sec.gov) (status valid, confidence 0.95). ### When did Gilead Sciences's revenue last change? The latest value on the record is $29.44 billion, dated December 31, 2025; before it the record holds $28.75 billion, dated December 31, 2024 and closed on December 31, 2025. ### What was Gilead Sciences's revenue before $29.44 billion? $28.75 billion, valid from December 31, 2024 to December 31, 2025 (status superseded), from a primary source (sec.gov). ## Read on - This page: /record/gilead-sciences/revenue (markdown: /record/gilead-sciences/revenue.md) - Entity twin: /record/gilead-sciences.md ยท timeline: /timelines/gilead-sciences.md - Every company's revenue: /facts/revenue.md --- AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.